Loading…
Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.
Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.
Has no approved medicine, so income comes from partners: upfront and milestone payments from Sanofi and Gilead under research collaborations and licences. Spending goes on clinical trials of its own oral drugs, led by KT-621 for immune diseases. The business is funded by partner payments and cash raised from investors.
Moat: narrow (IP / patents, process know-how). Early leadership in oral targeted-protein-degrader chemistry, patent-protected, with validated pharma partnerships.
Headquarters: Watertown, Massachusetts, US · Founded: 2016 · Employees: 238
Size Kymera Therapeutics (KYMR) is a United States Health Care company (Biotechnology) with a market value of $11.2B, the 726th largest of 3,117 United States companies the cockpit tracks. Shares closed at $131.73 on 6 Nov 2026.
Performance Over six months the shares gained 53.0%, against +9.0% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 133.8% over the last twelve months (peer median +26.0%); the operating margin is -396.0% (peer median 12.3%).
Valuation It trades at 101.2× enterprise value to sales against a peer median of 9.4× (2nd most expensive of 18).
Capital Return on invested capital runs 59.4 points below its cost of capital (15.0% WACC).
Backlog Backlog (remaining performance obligations) was $51.4M at 31 Dec 2024 — 1.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 11.0% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $102M | $39.2M | $47.1M | $78.6M | $46.8M |
| Revenue growth | — | -17% | -40% | +68% | — |
| Gross profit | $94.1M | $30.9M | $39.7M | $75.0M | $43.8M |
| EBITDA | -$397M | -$337M | -$249M | -$162M | -$158M |
| Net income | -$349M | -$311M | -$224M | -$147M | -$155M |
| Free cash flow | -$289M | -$234M | -$207M | -$137M | -$156M |
| Capital expenditure | $1.33M | $1.45M | $12.8M | $34.5M | $2.84M |
| Total debt | $76.6M | $82.3M | $87.8M | $84.7M | $17.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | $11.2B | +53% | +134% | -396% | 101.2× | n/a |
| Arvinas ARVN | $420M | -37% | -12% | -10% | n/a | n/a |
| C4 Therapeutics CCCC | $381M | +5% | +2% | -288% | 5.3× | n/a |
| Nurix Therapeutics NRIX | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KYMR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.5% | -4.6% | highest of 21 |
| 6-month return | +53.0% | +9.0% | 6th highest of 21 |
| Distance from 52-week high | -4.5% | -26.1% | 2nd highest of 21 |
| Revenue growth (TTM) | +133.8% | +26.0% | 3rd highest of 18 |
| Operating margin | -396.0% | 12.3% | 2nd lowest of 18 |
| EV / Sales | 101.2× | 9.4× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -59.4 pp | -0.7 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% | +0.1% |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 3.2× | 34.8% | +7.6% |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% | +26.0% |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | 18.3× | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Neurocrine Biosciences NBIX | United States | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% | +22.3% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
Kymera Therapeutics reported $51.4M of remaining performance obligations at 31 Dec 2024 and up 3% from the previous quarter. That is 1.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.23.